Review articles (reverse chronological order)


1.      Aksnes H, Ree R, Arnesen T (2019) Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal Acetyltransferases. Mol Cell 73(6):1097-1114.

2.      Ree R, Varland S, Arnesen T (2018) Spotlight on protein N-terminal acetylation. Exp Mol Med 50(7):90.


3.      Aksnes H, Drazic A, Marie M, Arnesen T (2016) First Things First: Vital Protein Marks by N-Terminal Acetyltransferases. Trends Biochem Sci 41(9):746-60.


44.      Drazic A, Myklebust LM, Ree R, Arnesen T (2016) The world of protein acetylation. Biochim Biophys Acta 1864(10):1372-401.


5.      Varland S, Osberg C, Arnesen T (2015) N-terminal modifications of cellular proteins: the enzymes involved, their substrate specificities and biological effects. Proteomics15(14):2385-401.


6.      Kalvik TV and Arnesen T (2013) Protein N-terminal acetyltransferases in cancer. Oncogene 32(3):269-76.


7.      Starheim KK, Gevaert K, Arnesen T (2012) Protein N-terminal acetyltransferases: when the start matters. Trends Biochem Sci 37(4):152-61.


8.      Van Damme P, Arnesen T, Gevaert K (2011) Protein alpha-N-acetylation studied by N-terminomics. FEBS J 278(20):3822-34. 


9.      Arnesen T. (2011) Towards a functional understanding of protein N-terminal acetylation. PLoS Biology 9(5): e1001074.


10.      Starheim KK, Gromyko D, Velde R, Varhaug JE, Arnesen T. (2009) Composition and biological significance of the human Nα-terminal acetyltransferasesBMC Proc. 3 (Suppl 6):S3


11.      Polevoda B, Arnesen T, Sherman F. (2009) A synopsis of eukaryotic Nα-terminal acetyltransferases: nomenclature, subunits and substrates. BMC Proc. 3 (Suppl 6):S2.  


12.      Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR. (2008) The protein acetyltransferase ARD1 – a novel cancer drug target? Curr Cancer Drug Targets8:545-553.

Last updated March 14, 2019.